Boehringer Ingelheim (canada) Ltd.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Elise Ghiro

Montse Llinas-Brunet

Murray D Bailey

Nathalie Goudreau

Teddy Halmos

Jean Rancourt

Youla S Tsantrizos

Anne-Marie Faucher

Dominik M Wernic

Dale R Cameron

Marc-Andre Poupart

Punit R Bhardwaj

Pasquale Forgione

Marc-André Poupart

Sylvie Goulet

Vida J Gorys

Josee Bordeleau

Bruno Simoneau

Dale Cameron

Marc-Andr&eacute; Poupart

Francois Bilodeau

Punit K Bhardwaj

François Bilodeau

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

Racemates, diastereoisomers and optical isomers of a compound of formula (I):wherein

Hepatitis C inhibitor tri-peptides

Compounds of formula (I):  wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor dipeptide analogs

Compounds of formula (I): wherein R, R, X, R, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

Racemates, diastereolsomers and optical isomers of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

The invention relates to compounds of formula (I) wherein R', R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I). 

Hepatitis C inhibitor peptide analogs

Compounds of formula (I): wherein R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Compounds of formula I: wherein D, R, R, L, L, L, Rand Rare defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

Compounds of formula (I): wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

A racemate diastereoisomer and optical isomer of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

Compounds of formula (I): wherein Ris hydroxyl or sulfonamide derivative; Ris t-butyl or &#x2014;CH&#x2014;C(CH)or &#x2014;CH-cyclopentyl; Ris t-butyl or cyclohexyl and Ris cyclobutyl, cyclopentyl or cyclohexyl; or a pharmaceutically acceptable salt thereof, are described as useful as inhibitor of the HCV NS3 protease.

Growing community of inventors

Laval, Canada

Elise Ghiro